Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12233401 | 0.90 | TDP1 (0.67) | ALDH1A1LMNAKDM4ECYP2C9TDP1 | |
| SCHEMBL22861375 | 0.86 | ALDH1A1 (0.61) | GAAALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL22281957 | 0.84 | ALDH1A1 (0.59) | GAAALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL39968 | 0.84 | LMNA (0.58) | GAAALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL24242954 | 0.84 | ACHE (0.49) | ALDH1A1EPHX1SMN1; SMN2 | |
| SCHEMBL22861352 | 0.83 | ACHE (0.51) | ALDH1A1MAPK1EPHX1SMN1; SMN2 | |
| SCHEMBL2691461 | 0.83 | GAA (0.66) | GAAALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL2347336 | 0.82 | GAA (0.70) | GAAALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL13655375 | 0.82 | LMNA (0.84) | GAAALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL22861473 | 0.82 | ALDH1A1 (0.64) | GAAALDH1A1LMNAKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4272825-A2 | MTORC MODULATORS AND USES THEREOF | Aeovian Pharmaceuticals, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-11702429-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230013344-A1 | MTORC MODULATORS AND USES THEREOF | EVOTEC (FRANCE) SAS (FR) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702429-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | GAA 2390/4885ALDH1A1 4766/4885LMNA 4444/4885 |
| US-20230013344-A1 | MTORC MODULATORS AND USES THEREOF | MTOR, RICTOR, RPTOR | GAA 2390/4885ALDH1A1 4766/4885LMNA 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.